Rabinowitz Matthew sold $34.1M of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 100,000 shares of Natera, Inc. (NTRA) at an average of $340.97 ($328.09–$351.24, $34.10M total) across 28 trades over 2026-09-14 to 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Sep 17, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishMed
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a bearish signal, but the pre‑arranged nature tempers the impact.

02

Market read

Primary relevance is to NTRA shareholders; limited spillover to the broader biotech sector.

03

What to watch

Upcoming clinical trial data or FDA decisions could offset the negative signal from the insider sale.

Relevance 6/10Novelty 8/10Timing: today

Background

Form 4 filing disclosed an insider transaction by Natera's executive chairman.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Executive Chairman Matthew Rabinowitz sold 100,000 shares for $34.1M via a 10b5‑1 plan, reducing his stake to 2.13M shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size ($34M) is material for a mid‑cap biotech and was executed through a pre‑arranged plan, suggesting a planned liquidity need rather than panic, but the reduction in insider ownership is still a bearish signal.

Market effects

May raise questions about insider confidence in Natera's pipeline, potentially affecting other biotech peers.

Limited to US biotech investors; no broader regional effect.

Low; relevance confined to investors tracking Natera and related biotech sector.

Counterpoint

The 10b5‑1 plan indicates a routine liquidity event, not a lack of confidence; the stock could be oversold.

Key entities

  • Natera, Inc.

    US‑listed biotech company (ticker NTRA).

  • Matthew Rabinowitz

    Executive Chairman of Natera who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.